About
Founded in 2023 by Jordi Parramon, PhD and William Marks, MD and with the addition of Jon Lundt, PhD, the firm brings a deep commitment to helping those with neurodegenerative, neuropsychiatric, and neurodevelopmental disorders, such as Parkinson’s disease, bipolar disorder, and autism spectrum disorder. Adjacent to these sentinel disorders are many other brain disorders that are also within scope for Nexus NeuroTech Ventures.
Sector Focus
Healthcare
Autism
Diagnostics
Ultrasound
Therapy
Series Focus
Series B
Series F
Cheque Size
$21.5M - $150.0M
Score Breakdown
26Deal Activity
22Track Record
0Visibility
2Profile
85Community
0Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What type of investor is Nexus NeuroTech Ventures?
Founded in 2023 by Jordi Parramon, PhD and William Marks, MD and with the addition of Jon Lundt, PhD, the firm brings a deep commitment to helping those with neurodegenerative, neuropsychiatric, and neurodevelopmental disorders, such as Parkinson’s disease, bipolar disorder, and autism spectrum disorder. Adjacent to these sentinel disorders are many other brain disorders that are also within scope…
What kind of firm is Nexus NeuroTech Ventures?
Nexus NeuroTech Ventures is a Venture Capital.
Where is Nexus NeuroTech Ventures based?
Nexus NeuroTech Ventures is based in United States.
What sectors does Nexus NeuroTech Ventures focus on?
Nexus NeuroTech Ventures focuses on Healthcare, Autism, Diagnostics, Ultrasound.
Similar Investors